<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jang JY</submitter><funding>Forkhead BioTherapeutics</funding><funding>NCI/NIH</funding><funding>NCI NIH HHS</funding><funding>National Research Foundation of Korea</funding><funding>Leukemia and Lymphoma Society</funding><pagination>e160767</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9753996</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>132(24)</volume><pubmed_abstract>Targeting lineage-defined transcriptional dependencies has emerged as an effective therapeutic strategy in cancer treatment. Through screening for molecular vulnerabilities of mantle cell lymphoma (MCL), we identified a set of transcription factors (TFs) including FOXO1, EBF1, PAX5, and IRF4 that are essential for MCL propagation. Integrated chromatin immunoprecipitation and sequencing (ChIP-Seq) with transcriptional network reconstruction analysis revealed FOXO1 as a master regulator that acts upstream in the regulatory TF hierarchy. FOXO1 is both necessary and sufficient to drive MCL lineage commitment through supporting the lineage-specific transcription programs. We further show that FOXO1, but not its close paralog FOXO3, can reprogram myeloid leukemia cells and induce B-lineage gene </pubmed_abstract><journal>The Journal of clinical investigation</journal><pubmed_title>A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas.</pubmed_title><pmcid>PMC9753996</pmcid><funding_grant_id>201077</funding_grant_id><funding_grant_id>P30 CA016058</funding_grant_id><funding_grant_id>MCL7001–18</funding_grant_id><funding_grant_id>2021R1A6A3A03039136</funding_grant_id><funding_grant_id>P01 CA214274</funding_grant_id><funding_grant_id>CA214274</funding_grant_id><pubmed_authors>Yao J</pubmed_authors><pubmed_authors>Elemento O</pubmed_authors><pubmed_authors>Kluk MJ</pubmed_authors><pubmed_authors>Belvedere S</pubmed_authors><pubmed_authors>Baiocchi RA</pubmed_authors><pubmed_authors>Jang JY</pubmed_authors><pubmed_authors>Hwang I</pubmed_authors><pubmed_authors>Di Liberto M</pubmed_authors><pubmed_authors>Pan H</pubmed_authors><pubmed_authors>Zanettini C</pubmed_authors><pubmed_authors>Imada E</pubmed_authors><pubmed_authors>Zheng H</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Ballman KV</pubmed_authors><pubmed_authors>Paik J</pubmed_authors><pubmed_authors>Lin HV</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Cantley LC</pubmed_authors><pubmed_authors>Chen-Kiang S</pubmed_authors><pubmed_authors>Marchionni L</pubmed_authors><pubmed_authors>Alinari L</pubmed_authors><pubmed_authors>Lee Y</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Inghirami G</pubmed_authors></additional><is_claimable>false</is_claimable><name>A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas.</name><description>Targeting lineage-defined transcriptional dependencies has emerged as an effective therapeutic strategy in cancer treatment. Through screening for molecular vulnerabilities of mantle cell lymphoma (MCL), we identified a set of transcription factors (TFs) including FOXO1, EBF1, PAX5, and IRF4 that are essential for MCL propagation. Integrated chromatin immunoprecipitation and sequencing (ChIP-Seq) with transcriptional network reconstruction analysis revealed FOXO1 as a master regulator that acts upstream in the regulatory TF hierarchy. FOXO1 is both necessary and sufficient to drive MCL lineage commitment through supporting the lineage-specific transcription programs. We further show that FOXO1, but not its close paralog FOXO3, can reprogram myeloid leukemia cells and induce B-lineage gene </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2026-05-29T18:57:57.964Z</modification><creation>2025-04-19T22:45:43.484Z</creation></dates><accession>S-EPMC9753996</accession><cross_references><pubmed>36282572</pubmed><doi>10.1172/JCI160767</doi></cross_references></HashMap>